Read More

Orchard Therapeutics Announced Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Orchard Therapeutics (NASDAQ: ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy® (atidarsagene autotemcel) has been accepted for evaluation by the Swiss Agency for Therapeutic Products (Swissmedic) for the potential treatment of eligible patients with early-on

ORTX